arrow
J

Joanna Fay

beaumont hospital dublin
H指数:21
被引数:1,665

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Junctional Adhesion Molecule-A (JAM-A) Associates With High-Risk Disease in Multiple Myeloma Patients and a Structure-Based Rationally-Designed Peptide Inhibitor Attenuates Tumorigenic Features In Vitro and In Vivo

连接黏附分子-A(JAM-A)与多发性骨髓瘤患者的高风险疾病相关,且基于结构的理性设计肽抑制剂在体外和体内均能减弱致瘤特征

2026-05-011
OAAI
RETRACTED: Richards et al. Protein Tyrosine Phosphatase Non-Receptor 11 (PTPN11/Shp2) as a Driver Oncogene and a Novel Therapeutic Target in Non-Small Cell Lung Cancer (NSCLC). Int. J. Mol. Sci. 2023, 24, 10545

撤回:Richards等人。非受体型蛋白酪氨酸磷酸酶11(PTPN11/Shp2)作为非小细胞肺癌(NSCLC)中的驱动癌基因和新型治疗靶点。国际分子科学杂志,2023年,24卷,10545号

2026-04-290
OAAI
Serine-arginine protein kinase 1 (SRPK1) is under-expressed in mucinous colorectal cancer, and may mediate resistance to oxaliplatin

粘液性结直肠癌中丝氨酸-精氨酸蛋白激酶1 (SRPK1) 表达下调,并可能介导奥沙利铂耐药性。

2025-10-030
OAAI
Spatial transcriptomic analysis reveals local effects of intratumoral fusobacterial infection on DNA damage and immune signaling in rectal cancer

空间转录组分析揭示了肿瘤内梭杆菌感染对直肠癌DNA损伤和免疫信号的局部影响

2024-05-061
OAAI
Predictive modelling of response to neoadjuvant therapy in HER2+ breast cancer
2023-09-270
OA
Prognostic value of the 6-gene OncoMasTR test in hormone receptor-positive HER2-negative early-stage breast cancer: Comparative analysis with standard clinicopathological factors
2021-07-013
OAAI
The role of infiltrating lymphocytes in the neo-adjuvant treatment of women with HER2-positive breast cancer

浸润淋巴细胞在HER2-positive乳腺癌新辅助治疗中的作用

2021-05-134
OAAI
Targeting the PI3K and MAPK pathways to improve response to HER2-targeted therapies in HER2-positive gastric cancer
2021-05-0127
OAAI
Identification and clinical impact of potentially actionable somatic oncogenic mutations in solid tumor samples
2020-02-2212
OAAI
Frequency, impact and a preclinical study of novel ERBB gene family mutations in HER2-positive breast cancer

HER2-positive乳腺癌中ERBB基因家族新突变的频率,影响和临床前研究

2018-07-1311
OAAI